Deakin home > Deakin University Library > Deakin Research Online > Genetic and molecular diagnosis of severe congenital neutropenia

Genetic and molecular diagnosis of severe congenital neutropenia

Ward, Alister C. and Dale, David C. 2009, Genetic and molecular diagnosis of severe congenital neutropenia, Current opinion in hematology, vol. 16, no. 1, pp. 9-13.


Title Genetic and molecular diagnosis of severe congenital neutropenia
Author(s) Ward, Alister C.
Dale, David C.
Journal name Current opinion in hematology
Volume number 16
Issue number 1
Start page 9
End page 13
Publisher Lippincott Williams & Wilkins
Place of publication Philadelphia, Pa.
Publication date 2009-01
ISSN 1065-6251
1531-7048
Summary AB Purpose of review: Severe congenital neutropenia has been a well known hematological condition for over 50 years. Over this long period of time, the variable genetic causes and associated sequelae of the disease have been ascertained, and successful treatment strategies developed. Over the past 2 years, however, new studies have added greatly to our understanding of the molecular basis of the disease, details of which are presented in this review. Recent findings: Recent studies have elucidated a role for the unfolded protein response in mediating the pathogenic effects of ELA2 mutations, the most common mutation in severe congenital neutropenia (SCN) as well as cyclic neutropenia. Genetic lesions in HAX1 have also been identified in the original Kostmann pedigree representing the autosomal recessive form of SCN. An emerging theme is the convergence of these and other genetic lesions underlying SCN in enhancing neutrophil apoptosis. Other studies have revealed the importance of multiple independent mutations in these and other genes in SCN. Finally, the key role for signal transducer and activator of transcription 5 in mediating the effects of granulocyte colony-stimulating factor receptor truncation mutations in the development of myelodysplastic syndrome/acute myeloid leukemia following SCN has been elucidated. Summary: As the full spectrum of molecular mutations causing neutropenia emerges, it is becoming possible to differentiate patients into subtypes with different prognoses, for whom tailored therapies are indicated.
Field of Research 110202 Haematology
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2009
Copyright notice ©2009, Lippincott Williams & Wilkins, Inc.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30018571

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in Deakin Research Online is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in TR Web of Science
Scopus Citation Count Cited 16 times in Scopus
Access Statistics: 334 Abstract Views  -  Detailed Statistics
Created: Tue, 08 Sep 2009, 16:34:41 EST by Alister Ward